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Mice lacking CD4 T cells due to a knock-out mutation respond to vaccination with a replication-defective adenoviral
recombinant expressing the glycoprotein of rabies virus with a long-lasting virus-neutralizing antibody response. The
vaccine-induced B cells secrete antibodies that are mainly of IgG isotypes. The response can be enhanced upon boosterof CD8 T cells but requires the presence of CD3 cells c
INTRODUCTION
Antibodies are the prime correlate of vaccine-induced
protection to challenge with most viruses. In general, the
induction of antibodies to protein antigens requires the
activity of CD4 T helper cells (Noelle et al., 1989). These
T cells promote the activation and differentiation of B
cells into antibody-secreting plasma cells through cog-
nate interactions with antigen-expressing B cells and
through the secretion of cytokines that provide growth
and maturation signals. The induction of antibody re-
sponses to pathogen-derived proteins in experimental
animals lacking CD4 T cells has been reported (Bach-
mann et al., 1995; Szomolanyi-Tsuda et al., 2001). We
previously tested the role of different immune effector
mechanisms in providing protection to rabies virus chal-
lenge and obtained similar results (Xiang et al., 1995).
Rabies virus, a negative-stranded RNA virus of the
genus Lyssavirus encodes only five structural antigens,
three of which are major targets for different immune
responses. The rabies virus glycoprotein that forms tri-
mers on the bullet-shaped rabies virus particles and on
the surface of infected cells is the only viral antigen able
to elicit and bind virus-neutralizing antibodies, the prime
correlate of protection against a fatal infection with this
virus (Sikes et al., 1971; Schumacher et al., 1989). The
rabies virus glycoprotein in addition elicits CD4 and
CD8 T cell responses (Wiktor et al., 1984; Celis et al.,
1988). The rabies virus nucleoprotein is the primary tar-
get for T helper cells to rabies virus and, in addition,
elicits nonneutralizing antibodies (Dietzschold et al.,
1988; Ertl et al., 1989). The nominal phosphoprotein,397the NK1.1 markers. © 2003 Elsevier Science (USA)
which together with the nucleoprotein, the viral polymer-
ase, and the viral genome forms the ribonucleoprotein
complex, provides epitopes for CD8 T cells (Larson et
al., 1992). Vaccines expressing the rabies virus glyco-
protein induce protective immunity to peripheral or intra-
cerebral challenge with rabies virus (Wiktor et al., 1984;
Xiang et al., 1996; Zalan et al., 1979).
We showed previously that antibodies mediate protec-
tion upon vaccination with a vaccinia virus recombinant
expressing the rabies virus glycoprotein (VRG). CD8 T
cells played no role in limiting the spread of the virus
(Xaing et al., 1995). During these studies we observed
that mice lacking CD4 T cells developed virus-neutral-
izing antibodies to rabies upon vaccination with the VRG
vaccine and were rendered partially resistant to chal-
lenge with a potentially lethal dose of a mouse-virulent
strain of rabies virus. Here we further investigated the
basis of the antibody response to the rabies virus glyco-
protein in mice lacking CD4 T helper cells.
RESULTS
Mice develop T helper-independent antibodies to the
rabies virus glycoprotein upon systemic immunization
with the AdHu5rab.gp or AdC58rab.gp recombinant
vaccine
We initially characterized the antibody response to the
rabies virus glycoprotein upon mucosal or systemic im-
munization of CD4KO mice with the AdHu5rab.gp recom-
binant vaccine, using C57Bl/6 mice for comparison. For
some of the experiments, we tested in parallel the
AdC68rab.gp vaccine, which as previously reported
(Xiang et al., 2002) induces a strongly Th1-biased im-immunization, indicating the induction of B cell memory in th
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reported previously, C57Bl/6 mice developed a vigorous
long-lasting antibody response upon both intranasal and
subcutaneous immunization (Xiang et al., 1996, 1999; Fig.
1A). The response to mucosal, i.e., intranasal (i.n.) immu-
nization paralleled that of the response to subcutaneous
(sc) immunization at the early time points after vaccina-
tion. Nevertheless, administration of the vaccine to the
airways, the natural route of infection by adenovirus of
the human serotype 5, resulted in higher antibody titers
when tested 5 months later. Both vaccines elicited high
antibody titers upon intramuscular immunization in
C57Bl/6 mice when tested 2 weeks later (Fig. 1B). Using
this route of vaccination elicited higher titers upon
vaccination with the AdHu5rab.gp than with the
AdC68rab.gp vaccine as reported previously (Xiang et al.,
2002). Oral immunization also induced detectable anti-
body titers to rabies virus, which were lower in
AdHu5rab.gp-vaccinated mice than in AdC68rab.gp-im-
mune C57Bl/6 mice. CD4KO mice developed antibodies
to the rabies virus glycoprotein upon sc or intramuscular
(im) immunization (Figs. 1A and 1B). In contrast, i.n.
immunization with the AdHu5rab.gp vaccine or per os
vaccination with either of the two recombinant vaccines
failed to induce detectable serum antibodies to the ra-
bies virus glycoprotein in CD4KO mice. Antibody titers in
CD4KO mice generated by sc immunization persisted
during the 5-month duration of the experiment. Further-
more, antibodies to the rabies virus glycoprotein derived
from CD4KO mice had virus-neutralizing activity (Fig. 2A),
which correlates with our previous finding that vacci-
nated CD4KO mice are rendered partially protected to
rabies virus challenge (Xiang et al., 1995). Virus-neutral-
izing antibody titers in CD4KO and C57Bl/6 mice immu-
nized im or per os paralleled titers detected by ELISA;
they were lower in CD4KO than in normal C57Bl/6 mice
and they were higher upon im than upon oral vaccination
(Fig. 2B). Serum antibodies to rabies virus tested from
both CD4KO and C57Bl/6 mice at different time points
after i.n. or sc immunization showed a mixed isotype
profile with mainly IgG1, IgG2a, and IgG2b (Fig. 3). This
indicates that the immunoglobulin genes of B cells to
rabies virus had switched to mature antibody isotypes
even in the absence of CD4 T helper cells. Upon
booster immunization given 2 months later with a second
dose of the AdHu5rab.gp vaccine, CD4KO mice devel-
oped a booster response, suggesting that the initial
immunization had established a memory B cell response
(Fig. 4).
FIG. 1. (A) The antibody response to the rabies virus glycoprotein presented by the AdHu5rab.gp or AdC68rab.gp vaccine in C57Bl/6 and CD4KO
mice. Groups of five C57Bl/6 (upper panels) or CD4KO (lower panels) mice were immunized sc (open squares) or i.n. (solid squares) with 2  106
pfu of AdHu5rab.gp virus. Sera harvested 2, 4, and 22 week (wks) later were tested for antibodies to rabies virus by an ELISA. Data show the mean
of duplicate dilutions  SD. , normal mouse serum from C57Bl/6 or CD4KO mice. (B) Groups of C57Bl/6 or CD4KO mice were immunized im or per
os with 107 pfu of the AdHu5rab.gp (solid squares) or the AdC68rab.gp (squares with cross) vaccine. Sera were tested 2 weeks later for antibodies
to rabies virus. , normal mouse serum from C57Bl/6 mice.
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Knock-out mice commonly develop alternative path-
ways to compensate for their defect. We therefore tested
whether CD4 T cell-independent activation of B cells
could be achieved in mice depleted just prior to immu-
nization of CD4 T cells. For these experiments, C57Bl/6
mice were injected 3 times in 48-h intervals with the
monoclonal rat GK1.5 antibody to CD4. The following day
they were immunized with 5  106 plaque-forming units
(pfu) of the AdHu5rab.gp recombinant. As shown in Fig.
5, CD4 T cell-depleted C57Bl/6 mice developed low but
detectable antibody responses to the rabies virus glyco-
protein upon immunization with the AdHu5rab.gp virus.
The response was not as impressive as that seen in
AdHu5rab.gp-immunized CD4KO mice, indicating that
compensatory mechanisms present in the knock-out
mouse facilitated the CD4 T cell-independent B cell
response.
Phenotypic characterization of lymphocytes that
provide help to B cells in the absence
of CD4 T cells
We tested whether CD8 T cells provided help to B
cells. Mice of the 2KO strain, which due to a defect in
the 2-microglobulin chain lack expression of MHC
class I determinants and consequently CD8 T cells,
FIG. 2. (A) The AdHu5rab.gp vaccine induces a virus-neutralizing
antibody response in CD4KO mice. Sera from CD4KO mice immunized
with 2  106 pfu of AdHu5rab.gp virus and harvested before immuni-
zation and 7, 18, and 50 days later were tested for neutralization of
rabies virus. (B) CD4KO and C57Bl/6 mice were immunized im (solid
bars) or orally (striped bars) with 2 107 AdHu5rab.gp virus. Sera were
harvested 2 weeks later and tested by a neutralization assay.
FIG. 3. The isotype profile of antibodies to rabies virus in C57Bl/6 and
CD4KO mice vaccinated with the AdHu5rab.gp construct. Groups of
five C57Bl/6 (left) or CD4KO (right) mice were vaccinated with 2  106
pfu of the AdHu5rab.gp vaccine given sc (open bars) or i.n. (solid bars).
Sera were tested 4 weeks later for isotypes of antibodies to rabies
virus. Sera from naive C57Bl/6 or CD4KO mice were tested in parallel
(cross-hatched bars). Data show the means of duplicate readings
obtained with sera at a 1:800 dilution SD.
FIG. 4. AdHu5rab.gp-vaccinated CD4KO mice develop memory B cell
response to rabies virus. Groups of five CD4KO mice were vaccinated
sc with 107 pfu of the AdHu5rab.gp vaccine. A portion of the mice were
boosted 6 weeks later with a second dose of 107 pfu of AdHu5rab.gp
virus (); the remaining mice were not boosted (). The same day an
additional group of five mice was vaccinated with 107 pfu of
AdHu5rab.gp virus (µ). Mice were bled 7 days later, and antibodies to
rabies virus were measured using a serum from naive CD4KO mice ()
for comparison.
FIG. 5. The antibody response to the rabies virus glycoprotein as
presented by the AdHu5rab.gp vaccine in CD4 T cell-depleted
C57Bl/6 mice. Groups of 5 C57Bl/6 mice were treated three times in
2-day intervals with GK1.5 antibody (solid squares) or left untreated
(open squares). Mice were vaccinated 24 h after the last treatment with
the antibody with 107 pfu of the AdHu5rab.gp vaccine given sc. Mice
were bled 2 and 4 weeks later and antibody titers to rabies were
measured by an ELISA. , normal C57Bl/6 mouse serum.
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were depleted of CD4 T cells using the same regimen
described above for depletion of C57Bl/6 mice. CD4 T
cell-depleted as well as untreated 2KO mice were vac-
cinated with the AdHu5rab.gp vaccine given sc. Mice
were bled at several time points and serum antibody
titers to rabies virus were measured. As shown in Fig. 6,
untreated 2KO mice developed only low antibody titers
within 2 weeks after vaccination, which at that time point
where absent in the CD4 T cell-depleted mice. Never-
theless, at the later time points the antibody response in
untreated 2KO mice became more pronounced and
mice depleted of CD4 T cells developed reduced but
nevertheless detectable and statistically significant anti-
body titers to the rabies virus antigen, which were readily
detectable by titration and isotype-mapping experiments.
The response in untreated 2KO mice was at either time
point not as impressive as the response in vaccinated
C57Bl/6 mice, indicating that CD8 T cells or other im-
mune mechanisms relying on 2-microglobulin-associ-
ated target antigens promoted the B cell response. Not-
withstanding, titers of antibodies to rabies virus in CD4
T cell-depleted 2KO mice were comparable to those
induced in CD4 T cell-depleted C57Bl/6 mice, suggest-
ing that CD8 T cells were not required to provide help
to B cells in lieu of CD4 T cells.
The role of different lymphocyte subsets in providing
help to B cells in absence of CD4 T helper cells was
further investigated in a series of antibody-depletion ex-
periments (Fig. 7). CD4KO mice were depleted of CD3 T
cells using an antibody specific to the CD3 chain, of
CD8 T cells, or of natural killer cells. Natural killer (NK)
cells, which are composed of different subsets, were
treated either with a polyclonal antiserum to asialo-GM1
or a monoclonal antibody to NK1.1.
Depletion of CD3 chain-positive lymphocytes caused
nearly complete abrogation of the antibody response in
CD4KO mice. The remaining antibodies were of the IgM
isotype. Depletion of CD8 T cells shifted the kinetics of
the antibody response, which came with a delay but then
exceeded that in CD4KO mice that had functionally ac-
tive CD8 T cells. The two antibodies to NK cell markers
gave strikingly opposing results. Treatment of CD4KO
mice with the monoclonal antibody to NK1.1 strongly
reduced the antibody response, while treatment with the
serum to asialo-GM1 accelerated the response, causing
a transient increase in the initial antibody titers to rabies
virus. A similar initial increase was seen in CD4 T
cell-depleted C57Bl/6 mice vaccinated with the
AdHu5rab.gp vaccine upon treatment with anti-asiolo-
GM1 serum. MHC class II KO mice, which developed
only a marginal antibody response to the vaccine, devel-
oped, upon treatment with the anti-NK1.1 antibody, a
transiently increased antibody response to rabies virus
(Fig. 7B).
Sera from antibody-treated mice were tested for iso-
types of antibodies to rabies virus. Figure 8 shows these
data for one representative time point when antibody
titers in the treated groups were most readily detectable.
Depletion of C57Bl/6 or 2KO mice (of the same genetic
background) of CD4 T cells still resulted in low levels of
IgG antibodies to rabies virus upon vaccination; they
were mainly of the IgG2b isotype in C57Bl/6 mice and of
the IgG1 isotype in 2KO mice. Treatment with an anti-
body to CD3 abolished the IgG responses to the rabies
virus glycoprotein in CD4KO mice without affecting the
IgM response. Mice treated with the antiserum to asialo-
GM1 had a response that was slightly more biased
toward the Th2 pathway, i.e., they showed higher levels
of IgG1 antibodies than did the control CD4KO mice. This
may reflect a reduction in IFN- upon depletion of NK
cells, which would have lessened the incentive for Th1
responses. Mice depleted of NK1.1 cells showed a strong
overall reduction in antibody responses to rabies virus.
The increase observed in MHC class II KO mice treated
with the antibody to NK1.1 (Fig. 7B) reflected an augmen-
tation of IgM antibodies, while levels of rabies virus-
specific IgG1 and IgG2a antibodies were decreased in
NK1.1-depleted MHC class II KO mice.
DISCUSSION
Our results show that E1-deleted adenoviral vaccines
to rabies virus based on either AdHu5 or AdC68 vectors
can induce a T helper cell-independent B cell response
to the transgene product. B cells can be classified into
several subsets according to their phenotypic markers
and their anatomic location. B1 B cells which reside in
FIG. 6. The antibody response to the rabies virus glycoprotein as
presented by the AdHu5rab.gp vaccine in CD4 T cell-depleted 2KO
mice. Groups of 5 2KO mice were treated three times in 2-day
intervals with GK1.5 antibody (solid squares) or left untreated (open
squares). Mice were vaccinated 24 h after the last treatment with the
antibody with 107 pfu of the AdHu5rab.gp vaccine given sc. Mice were
bled 2 and 4 weeks later and antibody titers to rabies were measured
by an ELISA. , normal 2KO mouse serum.
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the peritoneal cavity can mount a rapid IgM response
independent of T helper cells (Baumgarth et al., 1999;
Fagarasan et al., 2000). Splenic B cells are subdivided
into those that reside in the marginal zone (MZ) of the
spleen and those that home to the follicles (Kraal, 1992).
MZ B cells similar to B1 B cells can mount an early
antibody response that does not depend on CD4 T cell
help and that may play a crucial role in providing early
protection against pathogens (Martin et al., 2001). Induc-
tion of MZ B cell responses is thought to require blood-
borne particular antigen. The uncensored response of
MZ B cells, which is predominantly of the IgM isotype, is
short-lived and fails to establish memory. The short-lived
IgM response to rabies virus observed in MHC class II
KO mice depleted of NK1.1 cells may reflect a response
of MZ B or B1 B cells. Nevertheless, it is unlikely that the
FIG. 7. The role of different lymphocyte subsets in promoting T helper cell-independent antibody responses to the rabies virus glycoprotein
presented by the AdHu5rab.gp vaccine. (A) The figure shows the results of a number of different experiments. In these experiments groups of four
to five CD4KO mice were treated with antibodies to a specific lymphocyte subset as shown in the graph. After three intraperitoneal injections of the
antibody, mice were vaccinated 24 h later with 107 pfu of the AdHu5rab.gp vaccine given sc. Mice were bled at several time points thereafter and
antibody titers were determined by an ELISA. The graphs show the data for two representative time points. The left graphs show the early time points,
the right graphs show the late time points. Sera from mice treated with the antibody to CD3 were tested 2 and 10 weeks after immunization; sera
from anti-CD8-treated mice were tested 2 and 5 weeks after immunization; sera from anti-asialo-GM1-treated mice were tested 3 and 6 weeks after
immunization; and sera from anti NK1.1-treated mice were tested 1 and 2 weeks after immunization. The open squares show the results for untreated
CD4KO mice, the solid squares show data for sera from antibody-treated CD4KO mice, and the  show the normal CD4KO mouse sera controls. (B)
MHC class II KO mice were depleted of NK1.1 cells, and sera were tested 2 and 4 weeks later for antibodies to rabies virus as described in the legend
to (A).
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T helper cell-independent B cell response in CD4KO
mice to the rabies virus vaccine reflects the activity of B1
or MZ B2 B cells. The response was predominately of
antibodies of IgG isotypes. It was long lived, and booster
immunizations demonstrated that the vaccination of
CD4KO mice had generated memory B cells to the rabies
virus glycoprotein.
Viruses with complex structures that carry repeats of a
pattern have been shown to activate B cells directly
without CD4 T cell help by cross-linking of the B cells’
Ig receptors (Bachmann et al., 1995). The adenoviral
recombinant only expresses the rabies virus glycopro-
tein upon the infection of cells. Although the rabies
protein forms trimers on the surface of infected cells, it
does not furnish the highly organized structure of a virion
with its numerous ordered repeats of a given surface
antigen. This potential pathway is therefore unlikely to
form the basis of the described CD4 T cell-independent
B cell response.
Although the B cell response to the transgene product
of the AdHu5rab.gp vaccine is partially independent of
CD4 T cells, it requires CD3 lymphocytes. CD8 T
cells, which may provide growth signals to B cells by the
secretion of cytokines such as IL-2, are not required for
induction of the CD4 T cell-independent B cell re-
sponse. CD8 T cells affect the antibody response even
in the presence of CD4 T cells, in as far as a lack of this
T cell subset in knock-out mice leads to an overall
reduced B cell response. The 2KO mice not only lack
CD8 T cells due to their inability to synthesize 2-
microglobulin but also are defective in the expression of
other 2-microglobulin-associated surface proteins such
as CD1 or FcR. We therefore tested for a role of CD8
T cells in CD4KO mice treated with depleting doses of an
antibody to CD8. CD8 T cell-depleted CD4KO mice
initially showed a delay in B cell responsiveness but at
later time points developed elevated antibody titers com-
pared to control CD4KO mice. This increase may reflect
the prolonged persistence of the adenovirus-encoded
antigens in the absence of CD8 T cells shown previ-
ously to cause rapid elimination of adenovirus-infected
cells (Yang et al., 1996). One could argue that the delayed
development of an antibody response to the rabies virus
glycoprotein in CD8 T cell-depleted CD4KO mice re-
flects the reappearance of bone marrow-derived CD8 T
cells that became activated due to residual antigen. This
is unlikely, as a similar phenomenon should have been
observed in mice depleted of CD3 T cells, which failed
to develop detectable antibody responses even when
tested 10 weeks after immunization. The response in
CD4 T cell-depleted 2KO mice was dominated by anti-
bodies of the IgG1 isotype, unlike the response in un-
treated 2KO mice that developed mainly IgG2a antibod-
ies. This indicates that in this mouse strain CD4 T cells
sponsored mainly a Th1 response while the alternative
pathway favored the induction of Th2-type B cell re-
sponses.
Natural killer cells were found to play a dominant role
in promoting the CD4 T cell-independent B cell re-
sponse, although their contribution appears rather com-
plex. Depletion of natural killer cells with an antibody to
asiolo-GM1, which is also expressed on other unrelated
cell subsets, accelerated the antibody response in
CD4KO mice, while depletion of natural killer cells with a
more specific monoclonal antibody to NK1.1 abrogated
the response. The different effects of distinct antibodies
on NK cells, which are increasingly noted as reflecting a
functionally heterogeneous subset of lymphocytes, have
been described (Morelli et al., 1992). Natural killer cells,
upon activation by viruses or IL-12, secrete large
amounts of IFN-. This cytokine has antiviral activity by
inhibiting a number of steps in viral protein production.
IFN- inhibits the activity of some viral promoters, such
as the early promoter of cytomegalovirus (Harms and
FIG. 8. Isotypes of antibodies to rabies in sera from AdHu5rab.gp-vaccinated mice depleted of lymphocyte subsets. Sera from similar groups of
mice described in the legends to Figs. 5–7 were tested for isotypes of antibodies to rabies virus. C57Bl/6 and 2KO mice were tested 4 weeks after
immunization, CD4KO mice treated with an antibody to CD3 were tested 10 weeks after immunization, CD4KO mice treated with anti-asiolo-GM1
serum were tested 6 weeks after immunization, and mice treated with the antibody to NK1.1 were tested 2 weeks after immunization. Open bars, sera
from untreated mice; solid bars, sera from antibody-treated mice; hatched bars, control sera from naive mice.
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Splitter, 1995; Qin et al., 1997), which drives the expres-
sion of the rabies virus glycoprotein in the AdHu5rab.gp
and AdC68rab.gp vaccines. Dampening of the trans-
gene’s promoter transcription at the height of the virus-
induced NK cell response early after application of the
vaccine would explain the shift in kinetics of the gener-
ation of antibodies observed upon treatment with the
anti-asiolo-GM1 antibody. This treatment also caused a
slight shift toward a Th2-linked B cell response sugges-
tive of lowered levels of IFN-. In contrast, treatment of
mice with an antibody to NK1.1 strongly reduced induc-
tion of the vaccine-induced antibody response in CD4KO
mice and the IgG, albeit not the IgM, response in MHC
class II KO mice. These data suggest that lymphocytes
expressing both T and NK cell markers previously
termed NK T cells provide help to antiviral B cells in
absence of CD4 T cells. NK T cells are generally CD4-
and CD8-negative and express an invariant, germline-
encoded T cell receptor (Lant and Bendelac, 1994). They
respond to ligands associated with a nonpolymorphic
MHC-like structure termed CD1 (Chen et al., 1997). While
humans express both group 1 (CD1a, CD1b, CD1c, and
CD1e) and group 2 (CD1d) CD1 structures, only the latter
is detected in mice (Park and Bendelac, 1994). CD1
molecules present mainly lipid antigens, such as those
derived from bacterial cell walls, or self-determinants
such as ceramides (Sieling et al., 1995), although the
binding of peptides has also been described (Castano et
al., 1995). CD1d, expressed on antigen-presenting cells,
such as dendritic cells, has a 30-Å long, 15-Å wide
binding groove that is lined with hydrophopic residues,
which favors the binding of hydrophilic lipids (Zeng et al.,
1997). Assembly and transport of CD1 molecules de-
pends on 2-microglobulin (Sugita et al., 1999), and
2KO mice thus express neither MHC class I nor CD1d
determinants. Upon activation, NK T cells secrete cyto-
kines including IL-4 or IFN- and chemokines such as
MCP-1 (reviewed in Baxter, 2000). NK T cells were shown
to contribute to a wide spectrum of immune responses,
including immune-mediated protection to challenge with
viruses, bacteria, or tumor cells. Due to the secretion of
IL-4, which sponsors Th2-type immune responses at the
expense of Th1-linked immunity, including the activation
of CD8 T cells, NK T cells were found to prevent auto-
immune disease and to contribute to the immune re-
sponse against parasites (Balmer and Devaney, 2002;
Wang et al., 2001).
Although our data imply that NK T cells promote the
activation of B cells in the absence of CD4 T helper
cells, their mode of action remains elusive. The replica-
tion-defective adenoviral vaccine is unlikely to provide a
lipid epitope that can associate with CD1d molecules.
Nevertheless, cells upon infection with these noncyto-
pathic viruses may release lipidous molecules that could
associate with CD1d and trigger a response of NK T
cells. Alternatively or in addition, dendritic cells that can
be transduced and in part activated by adenoviruses of
human serotype 5 (Zhong et al., 2000) or chimpanzee
serotype 68 (manuscript in preparation) may respond to
this insult with the release of cytokines that contribute to
the activation of NK T cells. Lack of a T helper cell-
independent B cell response upon i.n. or oral immunization
may reflect the absence of NK T cells in the intraepithelial
lymphocyte population of the airway or intestinal mucosa
as shown previously (Ohteki and MacDonald, 1994).
MATERIALS AND METHODS
Mice
Inbred C57Bl/6 and RAG mice were purchased from
The Jackson Laboratory (Bar Harbor, ME). Knock-out
mice, i.e., CD4KO mice lacking CD4 T helper cells,
2KO mice deficient in 2-microglobulin and hence lack-
ing CD8 T cells, and MHC class II knock-out mice
(MHCIIKO) lacking MHC class II expression and conse-
quently CD4 T cell responses were either bred at The
Wistar Institute or purchased from The Jackson Labora-
tory. Female mice were used at 6–12 weeks of age.
Cell lines
BHK-21 and 293 cells were maintained in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) and antibiotics. Hybridoma cells
secreting monoclonal antibodies to CD3 (YCD3, provided
by Dr. C. Janeway), CD4 [GK1.5, American Type Culture
Collection, Rockville, MD (ATCC)], and CD8 (53.6.7, ATCC)
or PK136 (NK1.1, ATCC) were maintained in DMEM sup-
plemented with 10% FBS.
Antibodies
High-titered antibody was produced from the available
hybridoma cells in the peritoneal cavity of pristane-
primed RAG mice injected with 106 hybridoma cells.
Ascitic fluid was harvested 8–12 days later, cleared of
cells, and kept at 20°C. Antibodies were titrated by
injecting mice three times at 2-day intervals with different
dilutions of the ascitic fluid. Splenocytes were tested
subsequently for the appropriate T cell subset by stain-
ing with directly labeled antibodies to the given lympho-
cyte subset and analysis by flow cytometry.
Dilutions of ascitic fluid that caused95% reduction of
the lymphocyte subset compared to that in control mice
were used for the described experiments. A serum
against asiolo-GM1 was purchased from Wako, Inc.
(Wako, TX) and used according to the manufacturer’s
specifications. Including a control antibody preparation
in the experiments did not influence the results. This
control was thus omitted.
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Viruses
The AdHu5rab.gp recombinant, an E-1-deleted adeno-
viral recombinant of human serotype 5 expressing the
glycoprotein of the Evelyn Rokitniki Abelseth strain of
rabies virus, has been described previously (Xiang et al.,
1996). Generation of the more recently developed E1-
deleted AdC68rab.gp vaccine expressing the same
transgene product in a simian adenovirus vector has
been reported (Farina et al., 2001). Both viral recombi-
nants were propagated and titrated on 293 cells. The
ERA strain of rabies virus was grown on BHK-21 cells,
purified by gradient centrifugation, and inactivated by
treatment with -propiolactone. The protein content of
the inactivated virus (ERA-BPL) was determined and ad-
justed to 1 mg/ml. The rabies strain of the CVS-11 strain
was propagated and titrated on BHK-21 cells.
Immunization of mice
Mice were immunized once or twice with 2–10  106
plaque-forming units of the AdHu5rab.gp or AdC68rab.gp
vaccine given subcutaneously, intranasally, intramuscu-
larly, or per os. Mice treated three times with antibodies
to a lymphocyte subset were immunized 24 h after the
last application of the antibody. Antibodies were not
reapplied after immunization. We had shown previously
that mice immunized with an adenoviral recombinant
expressing a viral antigen not derived from rabies virus
failed to generate a rabies virus-specific antibody re-
sponse. This control was thus not included in the de-
scribed set of experiments. Otherwise, experiments
were repeated two to five times to ensure reproducibility.
Enzyme-linked immunoadsorbent assay
Sera were tested on rabies virus-coated plates as
described previously (Xiang et al., 1996). Briefly, round-
bottom microtiter plate wells were coated overnight with
0.2 g of ERA-BPL virus diluted in 100 l of coating buffer
(15 mM Na2CO3, 35 mM NaHCO3 and 3 mM Na2N, pH
9.6). The next day the plates were treated for 24 h with
phosphate-buffered saline (PBS) containing 3% bovine
serum albumin (BSA). The following day plates were
washed two times with 150 l of PBS for 24 h, dried, and
kept at 20°C. Sera were serially diluted in PBS con-
taining 3% BSA. The different dilutions were incubated in
duplicates at 100 l per well on the ERA-BPL-coated
plates for 1 h at 4°C. Plates were washed 5 with PBS
and treated with an alkaline phosphatase-conjugated
goat anti-mouse Ig for 1 h at 4°C. Plates were washed
and incubated for 20 min with the substrate (10 mg
d-nitrophenyl phosphate disodium dissolved in 10 ml of 1
mM MgCl2, 3 mM NaN3 and 0.9 M diethanolamine, pH
9.8). Plates were then read in an automated ELISA
reader at 405 nm.
Isotypes of antibodies to rabies virus were tested on
ERA-BPL-coated plates with a 1:400 dilution of sera us-
ing the Calbiochem (San Diego, CA) isotyping kit, which
has comparable sensitivity for different antibody iso-
types.
Virus-neutralization assay
Sera were tested for neutralization of the CVS-11 virus,
which is antigenically closely related to the ERA virus, on
BHK-21 cells as described (Zalan et al., 1979).
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